Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO).
Fiche publication
Date publication
octobre 2020
Journal
HemaSphere
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FEUGIER Pierre, Pr FORNECKER Luc-Matthieu, Pr DELMER Alain
Tous les auteurs :
Quinquenel A, Aurran-Schleinitz T, Clavert A, Cymbalista F, Dartigeas C, Davi F, de Guibert S, Delmer A, Dilhuydy MS, Feugier P, Fornecker LM, Ghez D, Guieze R, Laribi K, Leblond V, Leprêtre S, Letestu R, Lévy V, Nguyen-Khac F, Michallet AS, Tomowiak C, Tournilhac O, Ysebaert L, Troussard X
Lien Pubmed
Résumé
As a result of significant recent developments, the management of patients with chronic lymphocytic leukemia (CLL) is changing, and new therapeutic options will continue to emerge in the near future. The recommendations of the French Innovative Leukemia Organization (FILO-CLL) group presented here are intended to provide practical recommendations for physicians taking care of CLL patients, taking into account the availability of both biological tests and therapies in daily practice in France at the time of publication. This text details the documented information and guidelines on diagnosis, indications for treatment, infectious complications and therapeutic strategies in frontline and relapsed CLL as well as in particular conditions such as autoimmune cytopenia or Richter syndrome.
Référence
Hemasphere. 2020 Oct;4(5):e473